Efficacy and safety of combination therapy with pegylated interferon and ribavirin in aged patients with chronic hepatitis C
Poster
Data di Pubblicazione:
2012
Citazione:
Efficacy and safety of combination therapy with pegylated interferon
and ribavirin in aged patients with chronic hepatitis C / G., Abbati; Ventura, Paolo; Sardini, Carla; A., Vegetti; Pileri, Francesca; Cagnacci, Sara; Venturelli, Giorgia; Incerti, Federica; Pietrangelo, Antonello. - In: DIGESTIVE AND LIVER DISEASE. - ISSN 1590-8658. - ELETTRONICO. - 44 supplement 1:(2012), pp. 35S-35S.
Abstract:
Background & Aims: Combination therapy with pegylated interferon (PEGIFN)
and ribavirin has significantly improved virus eradication rate in patients
affected by HCV-related chronic hepatitis (C-HC). However, only few data are
available with respect to efficacy and safety of this therapy in aged patients.
This study aimed at investigating efficacy and tolerability of combination
therapy in aged patients with CH-C.
Methods: 473 patients [319 (67.4%) naive, 195 (41,2% female) with CH-C
(genotype 1, n=266; genotype 2, n=112, genotype 3, n=72, genotype 4, n=23),
of whom 68 (14.4%) over 65 years old (mean age 69±2 years), were treated
with Peg-IFN (alpha-2a or alpha-2b) plus ribavirin according to international
guidelines from January 2007 to July 2011. These patients were assessed for
sustained viral response (SVR) rate and for all known main predictors of SVR
in CH-C.
Results: The overall SVR rate resulted similar in both age groups [270/405
(66.6%) in subjects <65 years vs. 41/68 (60.3%) in subjects ≥65 years,
respectively, p=0.334)]. Overall, therapy discontinuance rate was low, with no
significant difference between patients over or under age 65 (4.4% vs. 4.9%,
respectively), the most common reason for discontinuance being anemia in
both groups.For patients over 65, at multivariate analysis, non-naïve status,
EVR and use of hematological growth factors were independent predictors
of SVR. Factors independently related to EVR at multivariate analysis were
non-naive, staging, genotype 2-3 vs. genotype1-4 and use of hematological
growth factors
Conclusions: Aged patients can be candidates for Peg-IFN plus ribavirin
therapy. The appropriate use of hematological factors in these patients may
be useful to achieve a significant reduction in the rate of therapy discontinuation
due to hematological side-effects. The response-guided therapy may be
applied in predicting therapy efficacy in this patient group
Tipologia CRIS:
Poster
Keywords:
Hepatitis C; pegylated interferon; ribavirin; aged patients
Elenco autori:
G., Abbati; Ventura, Paolo; Sardini, Carla; A., Vegetti; Pileri, Francesca; Cagnacci, Sara; Venturelli, Giorgia; Incerti, Federica; Pietrangelo, Antonello
Link alla scheda completa:
Titolo del libro:
Abstracts of the 45th A.I.S.F. - Italian Association for the
Pubblicato in: